Skip to main content

300 Collins St Melbourne hello@pivot.net

Main navigation

About
Research & Development
Pipeline
Investors
Careers

Translating Frontier Oncology Targets to Outsmart Cancer

September 19, 2019

Jacqueline A. M. Smith

RAS-Targeted Drug Discovery, Sept 17-19, 2019, Boston, MA

Download presentation

Return to Media Home

Latest Scientific Presentations

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

Enhancement of anti-tumor immunity in immunogenic and immune-refractory RAS mutant tumors with tri-complex RAS(ON) inhibitors

The Bi-steric mTORC1-Selective Inhibitor RMC-5552 in Tumors with Activation of mTOR Signaling: Preclinical Activity in Combination with RAS(ON) Inhibitors in RAS-Addicted Tumors, and Initial Clinical Findings from A Single Agent Phase 1/1b Study

RMC-6291, a Next-Generation Tri-Complex KRAS-G12C(ON) Inhibitor, Outperforms KRAS-G12C(OFF) Inhibitors in Preclinical Models of KRAS-G12C Cancers

Translating Frontier Oncology Targets to Outsmart RAS-Addicted Cancers

© Revolution Medicines, Inc. | 700 Saginaw Drive, Redwood City, CA 94063
CCPA Notice | Privacy Policy

Get in touch with us